FDA Reshapes Drug Testing Approach - Takeaways - MDSpire

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

  • By

  • Kathryn Wighton

  • April 20, 2026

  • 2 min

Share

  • 1

    The FDA is implementing a roadmap to reduce animal testing in drug development by 2025, meeting initial milestones.

  • 2

    Alternative methods, such as in vitro systems and computational modeling, are being advanced to improve drug testing accuracy.

  • 3

    Over 90% of drugs deemed safe in animal studies fail during human trials due to safety or efficacy issues.

  • 4

    The FDA has issued guidance to eliminate nonhuman primate testing and reduce horseshoe crab-derived endotoxin testing.

  • 5

    Collaboration with international regulators and NIH supports the FDA's efforts to improve drug safety predictions and reduce animal use.

Original Source(s)

FDA Reshapes Drug Testing Approach

  • by Kathryn Wighton

  • April 20, 2026

Related Content

The Mental Health Gap Doctors Don’t Close

National survey data also suggested lower treatment rates among health care workers with either condition.

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Cognition Associated With Future Depression Risk

Lower cognition is associated with later depression in controls, while higher cognition is associated with relapse in remitted depression